Generalist outbound agencies can’t see the hospital market (2026)

In France, any hospital purchase of supplies above €216,000 excluding VAT must go through a formal, published procurement procedure (2026 EU thresholds, Legal Affairs Directorate of France’s Ministry of the Economy). This market isn’t decided on LinkedIn: it opens on BOAMP (France’s official public procurement bulletin), often weeks before any generalist sales rep hears about it.

That’s the first reason a horizontal outbound agency can’t sell to a French hospital. Its playbook (LinkedIn, Apollo, high-volume cold email) is built for standard B2B buying, where you identify a decision-maker and reach out to them. Hospital purchasing, by contrast, starts with public procurement, gets approved by a committee, and is announced in regulatory registries that no generalist tool aggregates. The problem isn’t the agency’s effort. It’s that the agency is looking in the wrong place.

This article explains why the standard outbound playbook is blind to the healthcare market, who actually makes hospital purchasing decisions, where the real moat in MedTech prospecting lies, and what specialization concretely changes.

Why does French hospital purchasing slip past the standard outbound playbook?

Because the buying window opens with a public event, not a LinkedIn profile. In MedTech, an opportunity is born from a BOAMP tender, an equipment authorization from an ARS (regional health agency), an expiring HAS (France’s National Authority for Health) certification, or the appointment of a head of department. None of these triggers shows up in a generalist prospecting tool, which can only read LinkedIn and company databases. So the horizontal agency always arrives late: by the time the contract is public, the buyer has already drawn up its list of suppliers.

The regulatory framework makes this dynamic structural. Above €216,000 excluding VAT for supplies and services, a healthcare facility is required to publish its contract; the 2026 EU thresholds even lower this floor slightly from the previous €221,000 excluding VAT. A CT scanner, imaging software, an implantable device: most significant MedTech purchases cross this threshold and therefore become public notices. The signal exists, it’s dated, and it’s accessible. You still have to monitor it, which the standard outbound playbook doesn’t do.

This gap explains why an identity tool like Sales Navigator misses the hospital market: it knows who exists, never when a facility opens its budget. An agency that relies on it alone reproduces the same blind spot across every one of its campaigns.

Who really makes purchasing decisions in a hospital, and why does a generalist agency miss them?

No one person. A complex B2B purchase already involves 6 to 10 decision-makers, each arriving with their own research (Gartner, The B2B Buying Journey). In a hospital, that committee is layered on top of its own chain: the prescribing head of department, the purchasing director, the biomedical engineer, the finance department, and sometimes the commission médicale d’établissement (the hospital’s medical staff committee). The lone LinkedIn contact a generalist agency targets is just one link in the chain, and rarely the one who signs.

The structure makes things even more fragmented. Every French public healthcare facility is required to belong to one of the 135 GHTs (regional public hospital groups) created by the 2016 loi de modernisation du système de santé (health system modernization act): purchasing is often pooled at the group level, moving the decision outside the facility the rep thought they were targeting. An agency that doesn’t know this map sends its message to the wrong door.

On top of that comes a prospecting truth that volume doesn’t fix: at any given moment, only about 5% of buyers in a market are actually in buying mode, and the other 95% aren’t (LinkedIn B2B Institute with the Ehrenberg-Bass Institute, How B2B Brands Grow). Without a timing signal, a mass campaign mostly reaches the 95% who won’t move, which is exactly why generic cold email is dead in 2026. Sending more doesn’t solve the problem; it amplifies it.

What is the real moat in MedTech prospecting, and why can’t volume replace it?

Expert reading of public health data sources that nobody monitors systematically. The moat isn’t the ability to send more messages; it’s cross-referencing RPPS (France’s national registry of healthcare professionals), BOAMP, HAS, ARS, and Hospimedia to know when a facility enters a buying phase and why. A horizontal agency has never built these connectors: they’re worthless for its other accounts (SaaS, manufacturing, services), so it doesn’t develop them. Specialization isn’t a marketing argument; it’s technical debt the generalist has no interest in paying.

This gap is measurable. For a French MedTech company specializing in medical imaging, cross-referencing more than ten public sources made it possible, in six weeks, to keep only the truly qualified European radiologists, as detailed in this case study on prospecting radiologists through buying signals. No volume campaign on a purchased database would have produced that result: it’s not the number of names that qualifies a list, it’s the continuous reading of the signals around them. It’s the same reason a purchased B2B healthcare database is already a dead asset: it contains identities, never the buying signal.

That shift, from undifferentiated volume to monitoring industry-specific signals, is exactly what we scope during a conversation about your specific MedTech market: translating a product catalog into public events to track, rather than lists to contact. That’s Agify’s work: rebuilding the target with every signal detected instead of pushing a static file.

How do you recognize an agency that can sell to hospitals?

By its sources, not its sending volume. An agency that can genuinely prospect the French hospital market can name the registries it monitors (BOAMP, RPPS, HAS, ARS, and FINESS, France’s national registry of healthcare facilities), explain how it cross-references them, and reason in dated buying signals rather than message quotas. If the offer boils down to LinkedIn and cold email at scale, the regulatory blind spot remains intact, whatever industry the website claims.

The test is simple. Ask the agency where, in its view, a CT scanner purchase at a CHU (university hospital) begins. If the answer is about targeting the director on LinkedIn, that’s a horizontal playbook. If it’s about a tender to monitor, an ARS authorization, or a GHT that pools the decision, that’s someone who knows the terrain. Specialization shows at this level of granularity, as detailed in the guide to MedTech prospecting in France.

So the choice isn’t generalist versus specialist on price or promised volume. It comes down to a single question: does the agency see the market where it’s actually decided, or only where it’s easy to prospect?

Frequently asked questions

Can a generalist outbound agency really fail in MedTech when it succeeds elsewhere?

Yes, and it makes sense. Its success elsewhere comes from a playbook suited to standard B2B purchasing, where you target a decision-maker on LinkedIn. The hospital market moves the decision into public procurement, a committee, and a regional structure that this playbook can’t read. Competence isn’t the issue; the terrain is different.

Why does public procurement change the game for healthcare prospecting?

Because it makes purchasing visible and dated. Above €216,000 excluding VAT for supplies, a facility publishes its contract (2026 EU thresholds). That turns a private intention into a usable public signal, as long as you monitor BOAMP. An agency that only reads LinkedIn never sees that signal.

Is MedTech specialization just a sales pitch?

No, it’s infrastructure. Cross-referencing RPPS, BOAMP, HAS, and ARS requires connectors that are built and maintained, with no value in other industries. A horizontal agency has no reason to develop them. The difference shows in the sources the agency can name and cross-reference, not in its messaging.

Should you bring prospecting in-house rather than outsource it to an agency?

The question isn’t in-house versus outsourced, but generalist versus specialized. An in-house team without access to public health data sources reproduces the same blind spot as a horizontal agency. What matters is expert reading of industry signals, whether it comes from an in-house agent or a specialized partner.

How long does a hospital buying signal stay actionable?

Not long. A tender, an appointment, or an expiring certification opens a window of a few weeks, after which the buyer has often finalized its list of suppliers. The value lies in how fast you react, which volume prospecting without signal monitoring can’t deliver.

Conclusion

A generalist outbound agency doesn’t fail with French hospitals for lack of effort, but by design. Its playbook looks at LinkedIn and company databases, while hospital purchasing is decided through public procurement above €216,000 excluding VAT, approved by a committee of 6 to 10 decision-makers, and pooled across a regional hospital group. The signal exists, public and dated, but it lives in registries the generalist doesn’t monitor.

So the real dividing line isn’t promised volume or price; it’s the ability to read the market where it opens. Let’s spend 30 minutes together looking at which public sources announce your opportunities in your specific MedTech segment, and how to move from contacting lists to monitoring signals that reach you before the tender does.

---

Agify deploys autonomous AI prospecting agents within B2B sales teams, with a specialization in the French MedTech market and continuous reading of its public health and public procurement data sources.